(Q40698229)

22 September 2017

1 reference

title

Is there a correlation between serum antifungal drug concentration and clinical outcome? (English)

1 reference

22 September 2017

Graybill JR

1

1 reference

PubMed ID

8077687

22 September 2017

language of work or name

1 reference

1 May 1994

1 reference

22 September 2017

1 reference

22 September 2017

28 Suppl 1

1 reference

22 September 2017

17-24

1 reference

Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Clinical pharmacokinetics of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Pharmacokinetics of itraconazole following oral administration to normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Pharmacology and toxicity of high-dose ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Treatment of Candida albicans fungaemia with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Disseminated Infection with Fusarium in Recipients of Bone Marrow Transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Diagnosis and successful treatment of fusariosis in the compromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Scedosporium inflatum: clinical spectrum of a newly recognized pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Current role of therapy with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Trichosporonosis in patients with neoplastic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Amphotericin B in the treatment of coccidioidomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

Azole Antifungal Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

In vitro antifungal susceptibility testing and measurement of levels of antifungal agents in body fluids.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2995926-9

7 January 2021

10.1016/S0163-4453(94)95926-9

Identifiers

DOI

1 reference

release_qsvog64hkrhuphuuk26xdfmmyy

22 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qsvog64hkrhuphuuk26xdfmmyy

24 November 2022

mapped directly with Wikidata item

PubMed ID

8077687

1 reference

PubMed ID

8077687